يعرض 1 - 10 نتائج من 21 نتيجة بحث عن '"Laurence Eliot Miles Krieger"', وقت الاستعلام: 0.99s تنقيح النتائج
  1. 1
    Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

    المؤلفون: Laurence Eliot Miles Krieger, Eric Voog, Axel Heidenreich, Melanie Dowson, Simon Chowdhury, Jeremy Shapiro, Wassim Abida, Tony Golsorkhi, Ray McDermott, Richard Martin Bambury, Akash Patnaik, Axel S. Merseburger, Brieuc Sautois, Nicholas J. Vogelzang, Andrew Simmons, Gedske Daugaard, Josep M. Piulats, Darrin Despain, Celestia S. Higano, David Campbell, Karim Fizazi, Alan H. Bryce, Arif Hussain, Cora N. Sternberg, Jingsong Zhang, Simon Paul Watkins, Charles J. Ryan, Andrea Loehr

    المصدر: Clin Cancer Res

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, business.industry, medicine.drug_class, Concordance, medicine.disease, Androgen, Article, female genital diseases and pregnancy complications, Germline, chemistry.chemical_compound, Prostate cancer, chemistry, Antigen, Internal medicine, PARP inhibitor, medicine, Personalized medicine, skin and connective tissue diseases, Rucaparib, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9c5f34baf149bdd2024d2f3bfff3a0
    https://doi.org/10.1158/1078-0432.ccr-21-2199

    أضف إلى المفضلة
  2. 2
    Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

    المؤلفون: Laurence Eliot Miles Krieger, Arjun Vasant Balar, Petros Grivas, Eric A. Singer, Haojie Li, Tara L. Frenkl, Ashish M. Kamat, Girish S. Kulkarni, Badrinath R. Konety, Edward Uchio, Hiroyuki Nishiyama, Joost L. Boormans, Kijoeng Nam, Ekta Kapadia, Dean F. Bajorin, Ronald de Wit, Mathieu Roumiguié, Ho Kyung Seo

    المساهمون: Medical Oncology

    المصدر: The Lancet Oncology, 22(7), 919-930. Lancet Publishing Group

    مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Bladder cancer, business.industry, Standard treatment, Carcinoma in situ, medicine.medical_treatment, Population, 030232 urology & nephrology, Phases of clinical research, Pembrolizumab, medicine.disease, Cystectomy, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, education, Progressive disease

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310576cb36126232e3959fc6c4f2e4b8
    https://doi.org/10.1016/s1470-2045(21)00147-9

    View record from ScienceDirect Find this article in full text from ProQuest Full Text via ClinicalKey
    أضف إلى المفضلة
  3. 3
    Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

    المؤلفون: Jingsong Zhang, Simon Paul Watkins, Charles J. Ryan, Nicholas J. Vogelzang, David Campbell, Simon Chowdhury, Darrin Despain, Cora N. Sternberg, Andrea Loehr, Richard Martin Bambury, Gedske Daugaard, Josep M. Piulats, Wassim Abida, Karim Fizazi, Alan H. Bryce, Brieuc Sautois, Jeremy Shapiro, Andrew Simmons, Laurence Eliot Miles Krieger, Axel S. Merseburger, Eric Voog, Tony Golsorkhi, Melanie Dowson, Celestia S. Higano, Ray McDermott, Akash Patnaik, Axel Heidenreich

    المصدر: Abida, W, Patnaik, A, Campbell, D, Shapiro, J, Bryce, A H, McDermott, R, Sautois, B, Vogelzang, N J, Bambury, R M, Voog, E, Zhang, J, Piulats, J M, Ryan, C J, Merseburger, A S, Daugaard, G, Heidenreich, A, Fizazi, K, Higano, C S, Krieger, L E, Sternberg, C N, Watkins, S P, Despain, D, Simmons, A D, Loehr, A, Dowson, M, Golsorkhi, T, Chowdhury, S & TRITON2 investigators 2020, ' Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration ', Journal of Clinical Oncology, vol. 38, no. 32, pp. 3763-3772 . https://doi.org/10.1200/JCO.20.01035
    Journal of Clinical Oncology
    J Clin Oncol

    مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, 2019-20 coronavirus outbreak, Indoles, endocrine system diseases, Castration resistant, Poly(ADP-ribose) Polymerase Inhibitors, Genitourinary Cancer, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Germline mutation, Clinical Trials, Phase II as Topic, RAPID COMMUNICATIONS, Medicine, Humans, Progression-free survival, Neoplasm Metastasis, Rucaparib, Polymerase, Germ-Line Mutation, Aged, Aged, 80 and over, BRCA2 Protein, biology, business.industry, BRCA1 Protein, Editorials, Middle Aged, medicine.disease, Progression-Free Survival, Prostatic Neoplasms, Castration-Resistant, 030104 developmental biology, Oncology, chemistry, Gene Alteration, 030220 oncology & carcinogenesis, biology.protein, Cancer research, business

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271c7c2ada87d9db135e66207c386092
    https://curis.ku.dk/ws/files/256065464/Rucaparib_in_Men_with_Metastatic_Castration_Resistant_Prostate_Cancer_Harboring_a_BRCA1_or_BRCA2_Gene_Alteration.pdf

    أضف إلى المفضلة
  4. 4
    Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

    المؤلفون: Andrew Weickhardt, Carole A. Harris, Laurence Eliot Miles Krieger, Jeffrey C. Goh, Anthony M. Joshua, Arun Azad, Andrew Schmidt

    المصدر: Asia-Pacific journal of clinical oncologyREFERENCES. 15

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Alpha interferon, Angiogenesis Inhibitors, urologic and male genital diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, 030212 general & internal medicine, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Everolimus, business.industry, Sunitinib, Australia, Cancer, General Medicine, medicine.disease, Prognosis, Kidney Neoplasms, Clear cell renal cell carcinoma, chemistry, 030220 oncology & carcinogenesis, Immunotherapy, business, Lenvatinib, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3311ece4fcad44b08a9840523471f1
    https://pubmed.ncbi.nlm.nih.gov/31762165

    View record at Wiley
    أضف إلى المفضلة
  5. 5
    Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma

    المؤلفون: Anthony M. Joshua, Elizabeth Hovey, Jeffrey C. Goh, Craig Underhill, Emma Link, Craig Gedye, David Pook, Stephen Begbie, Francis Parnis, Laurence Eliot Miles Krieger, Michelle Frances Morris, Howard Gurney, Mathew George, New Zealand Urogenital, Tom Ferguson, Ian D. Davis, Prashanth Prithviraj, Ganessan Kichenadasse, Carole A. Harris, Michelle Harrison, Felicia Roncolato

    المصدر: Journal of Clinical Oncology. 39:4565-4565

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Ipilimumab, Immunotherapy, medicine.disease, Clear cell renal cell carcinoma, Refractory, Renal cell carcinoma, Internal medicine, Medicine, Nivolumab, business, Kidney disease, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::567830202f3797b10e7543c383e56e2c
    https://doi.org/10.1200/jco.2021.39.15_suppl.4565

    أضف إلى المفضلة
  6. 6
    Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

    المؤلفون: Mathieu Roumiguié, T. Saretsky, Laurence Eliot Miles Krieger, Petros Grivas, Kijoeng Nam, Eric A. Singer, Edward Uchio, Ekta Kapadia, B.R. Konethy, Ho Kyung Seo, Ashish M. Kamat, R. de Wit, Girish S. Kulkarni, Haojie Li, Dean F. Bajorin, Arjun Vasant Balar, Joost L. Boormans, Hiroyuki Nishiyama

    المصدر: European Urology Open Science, Vol 19, Iss, Pp e1173-e1174 (2020)

    مصطلحات موضوعية: Oncology, Bacillus (shape), medicine.medical_specialty, Bladder cancer, biology, business.industry, Urology, Phases of clinical research, Pembrolizumab, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, biology.organism_classification, lcsh:RC254-282, Internal medicine, medicine, business, Non muscle invasive

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7520a7198ac1efd2e8f15fbf4dd55d4
    https://doi.org/10.1016/s2666-1683(20)33372-3

    Full Text via ClinicalKey
    أضف إلى المفضلة
  7. 7
    Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

    المؤلفون: Eric A. Singer, Joost L. Boormans, Hiroyuki Nishiyama, Edward Uchio, Arjun Vasant Balar, Haojie Li, T. Saretsky, Ashish M. Kamat, R. de Wit, Mathieu Roumiguié, Eric Sbar, Girish S. Kulkarni, Petros Grivas, Laurence Eliot Miles Krieger, Kijoeng Nam, Ho Kyung Seo, Dean F. Bajorin, Badrinath R. Konety

    المصدر: Annals of Oncology. 30:v364-v365

    مصطلحات موضوعية: 0301 basic medicine, Antitumor activity, Health related quality of life, medicine.medical_specialty, business.industry, Bcg therapy, Stock options, Hematology, Metastatic bladder cancer, 03 medical and health sciences, Safety profile, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Family medicine, medicine, Non muscle invasive, business, Complete response

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5f8db4d5dd3b25d89e6a318dcc52b9cb
    https://doi.org/10.1093/annonc/mdz249.015

    أضف إلى المفضلة
  8. 8
    MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN

    المؤلفون: Tara L. Frenkl, Loic Mourey, Edward Uchio, Kijoeng Nam, Ronald de Wit, Ashish M. Kamat, Ekta Kapadia, Dean F. Bajorin, Joost L. Boormans, Badarinath Konety, Arjun Vasant Balar, Petros Grivas, Ho Kyung Seo, Girish S. Kulkarini, Eric A. Singer, Laurence Eliot Miles Krieger, Hiroyuku Nishiyama

    المصدر: Journal of Urology. 201

    مصطلحات موضوعية: Bacillus (shape), Oncology, medicine.medical_specialty, Bladder cancer, biology, business.industry, Urology, 030232 urology & nephrology, Pembrolizumab, biology.organism_classification, medicine.disease, complex mixtures, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, business, Non muscle invasive

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::923abd1ff4147af1d173b953f897d91a
    https://doi.org/10.1097/01.ju.0000556224.50163.ad

    View record from ScienceDirect
    أضف إلى المفضلة
  9. 9
    UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy

    المؤلفون: Tom Ferguson, Prashanth Prithviraj, Elizabeth Chien Hern Liow, Laurence Eliot Miles Krieger, David Pook, Michelle Harrison, Ian D. Davis, Michelle Frances Morris, Stephen Begbie, Carole A. Harris, Mathew George, Howard Gurney, Craig Gedye, Ganessan Kichenadasse, Craig Underhill, Felicia Roncolato, Elizabeth Hovey, Francis Parnis, Anthony M. Joshua, Jeffrey C. Goh

    المصدر: Journal of Clinical Oncology. 39:325-325

    مصطلحات موضوعية: Cancer Research, business.industry, Immune checkpoint inhibitors, Ipilimumab, medicine.disease, Clinical trial, Clear cell renal cell carcinoma, Oncology, Renal cell carcinoma, medicine, Cancer research, Nivolumab, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::23eececc9b164bc60587f256669390c5
    https://doi.org/10.1200/jco.2021.39.6_suppl.325

    أضف إلى المفضلة
  10. 10
    Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A

    المؤلفون: Joost L. Boormans, Petros Grivas, Kijoeng Nam, Arjun Vasant Balar, Mathieu Roumiguié, Ho Kyung Seo, Eric A. Singer, João Paulo Zambon, Ekta Kapadia, Edward Uchio, Ashish M. Kamat, Laurence Eliot Miles Krieger, Ronald de Wit, Badrinath R. Konety, Hiroyuki Nishiyama, Dean F. Bajorin, Girish S. Kulkarni

    المصدر: Journal of Clinical Oncology. 39:451-451

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Bladder cancer, business.industry, Pembrolizumab, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Cohort, medicine, Non muscle invasive, business, 030215 immunology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::443c856e8fa1c89231033d0120ff6dcb
    https://doi.org/10.1200/jco.2021.39.6_suppl.451

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء